Core Viewpoint - The company, 微电生理, is experiencing a decline in stock price and has a high price-to-earnings (PE) ratio compared to the industry average, indicating potential overvaluation in the market [1][3]. Company Overview - 微电生理 specializes in the development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2]. - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, focusing on precise interventional navigation [2]. Product Portfolio - Key products include the Columbus 3D cardiac electrophysiology mapping system, EasyFinder3D magnetic positioning adjustable mapping catheter, and various disposable mapping and ablation catheters [2]. - The company’s cryoablation devices and balloon-type cryoablation catheters have been recognized in the 2024 Shanghai "New Excellent Drugs and Devices" product directory [2]. Financial Performance - In Q1 2025, the company reported revenue of 1.04 billion yuan, a year-on-year increase of 16.77%, and a net profit of 178.7 million yuan, reflecting a significant year-on-year growth of 328.63% [3]. - The gross profit margin for the company stands at 60.56% [3]. Market Position - As of June 10, the company's stock price closed at 19.47 yuan, with a rolling PE ratio of 139.31, significantly higher than the industry average of 51.00 and the median of 37.03 [1][3]. - The total market capitalization of 微电生理 is 9.163 billion yuan [1]. Shareholder Information - As of March 31, 2025, the number of shareholders is 7,764, a decrease of 209 from the previous count, with an average holding value of 352,800 yuan per shareholder [1].

微电生理 2024 年年度股东大会会议资料 证券代码：688351 证券简称：微电生理 上海微创电生理医疗科技股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 18 日 1 / 28 微电生理 2024 年年度股东大会会议资料 目 录 | 年年度股东大会会议须知 2024 | | | 3 | | | --- | --- | --- | --- | --- | | 2024 年年度股东大会会议议程 | 5 | | | | | 议案一：关于《2024 | 年度董事会工作报告》的议案 | | | 7 | | 议案二：关于《2024 | 年度监事会工作报告》的议案 | | | 12 | | 议案三：关于《2024 | 年度独立董事履职情况报告》的议案 | | | 16 | | 议案四：关于 2024 | 年年度报告及其摘要的议案 | | | 17 | | 议案五：关于《2024 | 年度财务决算报告》的议案 | | | 18 | | 议案六：关于 2024 | 年度利润分配预案的议案 | | | 24 | | 议案七：关于 2025 | 年度日常关联交易预计的议案 | | | 25 | | 议案八 ...

Group 1 - The company Shanghai MicroPort EP MedTech Co., Ltd. will hold its annual general meeting on June 18, 2025 [1][3] - The voting method for the meeting will combine on-site and online voting through the Shanghai Stock Exchange network voting system [1][3] - Shareholders must register for the meeting by the close of trading on June 10, 2025, to be eligible to attend [4][5] Group 2 - The meeting will take place at the company's office located at 588 Long 23, Tianxiong Road, Zhoupu Town, Pudong New District, Shanghai [4][5] - Shareholders can vote via the trading system from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 on the day of the meeting [1][3] - The company has specified that related shareholders, such as MicroPort Investment Holdings Co., Ltd., should abstain from voting [3]

证券代码：688351 证券简称：微电生理 公告编号：2025-011 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 18 日 14 点 30 分 上海微创电生理医疗科技股份有限公司董事会 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 召开地点：上海市浦东新区周浦镇天雄路 588 弄 23 号楼 3 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 18 日 至2025 年 6 月 18 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年6月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络 ...

Core Viewpoint - The report highlights the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A, indicating a recent decline in net value but strong returns over various time frames [1]. Fund Performance - The latest net value of the fund is 1.5670 yuan, reflecting a decrease of 1.94% - Over the past month, the fund achieved a return of 3.91%, ranking 171 out of 1959 in its category - In the last three months, the fund's return was 22.33%, ranking 5 out of 1950 - Year-to-date, the fund has returned 30.15%, ranking 17 out of 1943 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 64.17%, with the following allocations: - Heng Rui Medicine: 10.23% - Kelun Pharmaceutical: 9.09% - Baile Tianheng: 8.94% - Haizike: 8.27% - Xinlitai: 6.66% - Zai Jian Pharmaceutical-U: 6.10% - Xin Nuo Wei: 4.69% - Rongchang Biotechnology: 3.49% - Nuocheng Jianhua-U: 3.35% - Microelectrophysiology: 3.35% [1]. Fund Background - The Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A was established on June 18, 2015, and as of March 31, 2025, it has a total scale of 4.408 billion yuan - The fund manager is Zhang Wei, who has extensive experience in the pharmaceutical sector [1][2].

证券代码：688351 证券简称：微电生理 公告编号：2025-010 上海微创电生理医疗科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 05 月 26 日(星期一) 至 05 月 30 日(星期五)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 investors@everpace.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 上海微创电生理医疗科技股份有限公司（以下简称"公司"）已于 2025 年 3 月 28 日、4 月 30 日分别披露了公司 2024 年年度报告及 2025 年第一季度报告， 为便于广大投资者更全面深入地了解公司2024年年度及2025年第一季度经营成 果、财务状况，公司计划于 2025 年 06 月 03 日（星期二）13:00-14:00 举行 20 ...

Core Viewpoint - The electrophysiology device market in China is experiencing rapid growth due to an aging population, increasing prevalence of arrhythmias, improved early screening rates, and advancements in electrophysiological procedures, with the market expected to reach over 40 billion yuan by 2032 [1][10][21]. Industry Overview - Electrophysiology devices are used to monitor and study electrical activities in biological systems, widely applied in medical, research, and clinical diagnosis fields. Common products include ECG machines, EEG machines, EMG machines, and electrophysiological navigation systems [2][4]. Industry Environment - The number of patients with rapid arrhythmias in China is projected to reach 28.2 million by 2024, driving demand for treatment. Electrophysiological surgeries have become a primary treatment method due to their advantages such as minimal invasiveness and high safety [6][8]. Industry Status - The market size for electrophysiology devices in China has grown from 2.42 billion yuan in 2017 to 12.55 billion yuan in 2024. The surgical volume for electrophysiology has increased from 138,000 cases in 2017 to 456,000 cases in 2024, indicating significant growth potential [10][8]. Competitive Landscape - The market is dominated by foreign companies such as Johnson & Johnson, Abbott, and Medtronic, which hold a combined market share of over 64%. Domestic companies like Huatai Medical and MicroPort EP have a much smaller share, indicating a high concentration in the industry [12][14]. Key Enterprises - MicroPort EP focuses on innovative medical devices for electrophysiology and has achieved significant revenue growth, with a projected income of 413 million yuan in 2024, up 25.51% [17]. Huatai Medical, specializing in electrophysiology and interventional medical devices, expects a revenue of 440 million yuan in 2024, reflecting a 19.73% increase [19]. Development Trends 1. **Accelerated Domestic Substitution**: Domestic brands are gaining market share due to supportive policies and technological advancements, with MicroPort EP and Huatai Medical leading in key areas [21]. 2. **Technological Innovation**: The industry is moving towards smart and precise technologies, enhancing the performance of electrophysiology devices and expanding clinical applications [22]. 3. **Growing Market Demand**: The demand for electrophysiology devices is surging, particularly in grassroots healthcare and international markets, with significant growth in overseas revenues for domestic companies [23].

Group 1 - The core business of the company is the development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, centered around precise interventional navigation [2] - The company has several key products, including the Columbus 3D cardiac electrophysiology mapping system and various disposable electrophysiological catheters [2] Group 2 - As of March 31, 2025, the company had 7,764 shareholders, a decrease of 209 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company reported a revenue of 104 million yuan in Q1 2025, representing a year-on-year increase of 16.77%, and a net profit of 17.87 million yuan, up 328.63% year-on-year, with a gross margin of 60.56% [3] - The company's rolling PE ratio reached 150.26, significantly higher than the industry average of 49.40 and the industry median of 36.13, ranking 112th in the industry [1][3]

Core Viewpoint - Microelectrophysiology has experienced a decline over four consecutive trading days, with a cumulative drop of -4.93% [1] Group 1: Company Overview - Shanghai MicroPort Electrophysiology Medical Technology Co., Ltd. was established on August 31, 2010, in the Shanghai International Medical Park [1] - The company has seen significant interest from funds, with two funds under Huatai-PineBridge entering the top ten shareholders of Microelectrophysiology [1] Group 2: Fund Performance - Huatai-PineBridge Medical Service Flexible Allocation Mixed A Fund has reduced its holdings in Microelectrophysiology, while Huatai-PineBridge Daxin Mixed A Fund has increased its holdings in the first quarter of this year [1] - The year-to-date return for Huatai-PineBridge Medical Service Flexible Allocation Mixed A Fund is 25.33%, ranking 23rd out of 2320 in its category [1] - The year-to-date return for Huatai-PineBridge Daxin Mixed A Fund is 26.09%, ranking 16th out of 2320 in its category [1] Group 3: Fund Manager Background - The fund managers for Huatai-PineBridge Medical Service Flexible Allocation Mixed A and Huatai-PineBridge Daxin Mixed A are Zhang Wei, who holds a Master's degree in Biomedical Engineering from Cornell University [3] - Zhang Wei has a background as an assistant researcher in pharmaceuticals at Dongfang Securities and has held various positions at Huatai-PineBridge, including leading the pharmaceutical research team [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within six months [15]. Core Insights - The company reported a significant increase in revenue and net profit for 2024, with revenue reaching 413 million yuan, a year-on-year growth of 25.51%, and net profit of 52 million yuan, a staggering increase of 815.36% [3][9]. - For Q1 2025, the company achieved a revenue of 104 million yuan, up 16.77% year-on-year, and a net profit of 18 million yuan, reflecting a growth of 328.63% [3]. - The company has expanded its market presence, with over 4,000 procedures performed using its pressure monitoring magnetic navigation radiofrequency ablation catheter in the domestic market, and has successfully conducted surgeries in 21 countries internationally [4][8]. Company Overview - The latest closing price of the company's stock is 21.64 yuan, with a total market capitalization of 10.2 billion yuan [2]. - The company has a total share capital of 471 million shares, with 125 million shares in circulation [2]. - The largest shareholder is Ningbo Meishan Bonded Port Area Huajie Equity Investment Management Co., Ltd. [2]. Financial Performance - The company forecasts revenue growth from 539 million yuan in 2025 to 956 million yuan in 2027, with corresponding year-on-year growth rates of 30.5%, 34.5%, and 31.9% respectively [9][11]. - The projected net profit for the same period is expected to rise from 74 million yuan in 2025 to 172 million yuan in 2027, with growth rates of 41.5%, 57.8%, and 47.6% [9][11]. - The company's PE ratio is projected to decrease from 142 times in 2025 to 61 times in 2027, indicating improving valuation metrics [9][11]. Product Development and Market Strategy - The company is focusing on enhancing its product matrix, including the launch of new products such as the Magbot™ catheter and the PulseMagic™ pressure pulse catheter, which are in various stages of regulatory approval [5][6]. - The company plans to increase its hospital coverage and promote core and new products in both domestic and international markets, aiming to enhance the penetration rate of its three-dimensional surgeries [8]